| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10211920 | Clinical Lymphoma Myeloma and Leukemia | 2018 | 25 Pages |
Abstract
The BuRP regimen was found to be safe in patients with R/R B-cell NHL. The favorable toxicity profile plus the encouraging response rates seen suggest that continued investigation of the highest dose level is warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Benjamin Heyman, David Rizzieri, David J. Adams, Carlos De Castro, Louis Diehl, Zhiguo Li, Joseph Moore, Anne Beaven,